Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Carsten, Hofmann"'
Autor:
Hans Peter Grimm, Vanessa Schumacher, Martin Schäfer, Sabine Imhof-Jung, Per-Ola Freskgård, Kevin Brady, Carsten Hofmann, Petra Rüger, Tilman Schlothauer, Ulrich Göpfert, Maximilian Hartl, Sylvia Rottach, Adrian Zwick, Shanon Seger, Rachel Neff, Jens Niewoehner, Niels Janssen
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTThere are few treatments that slow neurodegeneration in Alzheimer’s disease (AD), and while therapeutic antibodies are being investigated in clinical trials for AD treatment, their access to the central nervous system is restricted by the b
Externí odkaz:
https://doaj.org/article/1e3d18094e0b44a99ca3a99a2f9d46b6
Autor:
Vidya Ramakrishnan, Christina Friedrich, Colleen Witt, Robert Sheehan, Meghan Pryor, Jasvinder K. Atwal, Kristin Wildsmith, Katherine Kudrycki, Seung‐Hye Lee, Norman Mazer, Carsten Hofmann, Reina N. Fuji, Jin Y. Jin, Saroja Ramanujan, Michael Dolton, Angelica Quartino
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 1, Pp 62-73 (2023)
Abstract Despite considerable investment into potential therapeutic approaches for Alzheimer's disease (AD), currently approved treatment options are limited. Predictive modeling using quantitative systems pharmacology (QSP) can be used to guide the
Externí odkaz:
https://doaj.org/article/6c9f800424f0462f8528114142c69f0a
Autor:
Roxana Aldea, Hans Peter Grimm, Ronald Gieschke, Carsten Hofmann, Dominik Lott, Szofia Bullain, Paul Delmar, Gregory Klein, Marco Lyons, Fabrizio Piazza, Roxana O. Carare, Norman A. Mazer
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction Amyloid‐related imaging abnormalities with edema/effusion (ARIA‐E) are commonly observed with anti‐amyloid therapies in Alzheimer's disease. We developed a semi‐mechanistic, in silico model to understand the time course
Externí odkaz:
https://doaj.org/article/0b614bdc96e645a1b1ef006dde12af9c
Autor:
Gregory Klein, Paul Delmar, Nicola Voyle, Sunita Rehal, Carsten Hofmann, Danielle Abi-Saab, Mirjana Andjelkovic, Smiljana Ristic, Guoqiao Wang, Randall Bateman, Geoffrey A. Kerchner, Monika Baudler, Paulo Fontoura, Rachelle Doody
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-12 (2019)
Abstract Background We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor-mediated phagocytosis, in the SCarlet RoAD (SR) and Marguerite RoA
Externí odkaz:
https://doaj.org/article/29e25f8952e84cb1b1fdabb56ae549b5
Autor:
Susanne Ostrowitzki, Robert A. Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli, Paulo Fontoura, for the SCarlet RoAD Investigators
Publikováno v:
Alzheimer’s Research & Therapy, Vol 9, Iss 1, Pp 1-15 (2017)
Abstract Background Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safety of gantenerumab
Externí odkaz:
https://doaj.org/article/e955ede30f6c4f9ea14e0090bdf6615d
Autor:
Beate Bittner, Dietmar Schwab, Agnes Portron, Dominik Lott, Frank Boess, Rémy Kohler, Jakub Wojtowicz, Carsten Hofmann
Publikováno v:
Monday, April 24.
Autor:
Sylvie Retout, Ronald Gieschke, Daniel Serafin, Cornelia Weber, Nicolas Frey, Carsten Hofmann
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:857-866
Selecting the right dose is a significant challenge in designing clinical development programs, especially for slowly progressing diseases lacking predictive biomarkers of efficacy that may require long-term treatment to assess clinical benefit. Gant
Autor:
Frank Boess, Christopher Lane, Marzia A. Scelsi, Paul Delmar, Carsten Hofmann, Matteo Tonietto, Gregory Klein, Geoffrey A. Kerchner, Monika Baudler, Rachelle S. Doody
Publikováno v:
Alzheimer's & Dementia. 18
Autor:
Norman A Mazer, Carsten Hofmann, Dominik Lott, Ronald Gieschke, Gregory Klein, Frank Boess, Hans Peter Grimm, Geoffrey A. Kerchner, Monika Baudler, Janice Smith, Scott Schobel, Rachelle S. Doody
Publikováno v:
Alzheimer's & Dementia. 18
Autor:
Vidya Ramakrishnan, Christina Friedrich, Colleen Witt, Robert Sheehan, Meghan Pryor, Jasvinder K. Atwal, Kristin Wildsmith, Katherine Kudrycki, Seung‐Hye Lee, Norman Mazer, Carsten Hofmann, Reina N. Fuji, Jin Y. Jin, Saroja Ramanujan, Michael Dolton, Angelica Quartino
Publikováno v:
CPT: pharmacometricssystems pharmacologyREFERENCES.
Despite considerable investment into potential therapeutic approaches for Alzheimer's disease (AD), currently approved treatment options are limited. Predictive modeling using quantitative systems pharmacology (QSP) can be used to guide the design of